Eradicating hepatitis C: Are novel screening strategies for people who inject drugs cost-effective?

Viral hepatitis testing and treatment in community pharmacies: a systematic review and meta-analysis

“…Of the 26 included studies reporting hepatitis C outcomes, two studies did not contribute new hepatitis C data due to overlap with other studies, but were still included in the review as they contributed results relating to hepatitis B 29 and cost-effectiveness. 42 The designs of the remaining 24 studies are summarised in Table 2 and the results for the primary outcomes of (1) pre-testing risk assessment, (2) testing, (3) attendance at pre-treatment assessment and/or (4) treatment are summarised in Table 3 .…”

CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers

“…syringe exchange services) to increase screening and treatment receipt as well as to comply with economic requirements. 32 , 33 , 34 , 35 , 36 , 37 , 38 As demonstrated by the highly successful collaboration in this project, pharmacies represent institutions with great potential to contribute to HCV elimination, not only by supporting treatment adherence but also by expanding the capacity for decentralized screening/diagnostic testing, e.g. by offering point-of-care testing on-site.…”

Cost-effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: An economic evaluation alongside a pragmatic cluster randomised trial

“…24 , 25 A study assessing the cost-effectiveness of new communitybased HCV strategies in PWID (within substance misuse services, needle exchanges, and community pharmacies) also highlighted the impact alternative strategies can have on cost-effectiveness and supports the cost-effectiveness of community pharmacy-based testing, similarly finding drug price to be the main driver of costeffectiveness. 26 The im pact on uptake and cost-effectiveness that alternative HCV treatment strategies can have in PWID has also been shown using data from a RCT comparing primary and secondary care treatment with DAAs. 20 One study assessing the costeffectiveness of testing high-risk groups for HCV in community pharmacies using DBSTs found the strategy to be cost-effective, however, although still cost effective, the intervention was less efficient in PWID.…”